@article{3109112,
    title = "Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases",
    author = "Zarogoulidis, P. and Chinelis, P. and Athanasiadou, A. and Tsiouda, T. and Trakada, G. and Kallianos, A. and Veletza, L. and Hatzibougias, D. and Mihalopoulou, E. and Goupou, E. and Kosmidis, C. and Sardeli, C. and Huang, H. and Hohenforst-Schmidt, W.",
    journal = "Respiratory Medicine Case Reports",
    year = "2017",
    volume = "22",
    pages = "101-105",
    publisher = "W.B. Saunders Ltd",
    issn = "2213-0071",
    doi = "10.1016/j.rmcr.2017.07.004",
    keywords = "anaplastic lymphoma kinase;  carboplatin;  epidermal growth factor receptor;  gemcitabine;  methylprednisolone;  nivolumab;  paclitaxel;  pembrolizumab;  programmed death 1 ligand 1;  taxane derivative;  zoledronic acid, abdominal organ rupture;  adult;  adverse drug reaction;  aged;  Article;  cancer immunotherapy;  cancer patient;  cancer therapy;  case report;  follow up;  gene mutation;  human;  lung adenocarcinoma;  male;  multiple cycle treatment;  neutropenia;  non small cell lung cancer;  pharmacogenomics;  priority journal;  squamous cell lung carcinoma",
    abstract = "In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients. © 2017 The Authors"
}